Valproate, divalproex, valpromide: Are the differences in indications justified?

Area of Science:

• Pharmacology and Therapeutics
• Neuroscience
• Psychiatry

Background:

• Valproate (VPA) derivatives, divalproex (DVP) and valpromide (VPM), have distinct therapeutic indications compared to valproic acid (VA) in many countries.
• DVP is a combination of sodium valproate and valproic acid, while VPM is a prodrug hydrolyzed to VA.
• The active moiety across all formulations is the valproate ion.

Purpose of the Study:

• To review and analyze comparative studies on the efficacy, pharmacokinetics, side effects, and costs of valproic acid (VPA), divalproex (DVP), and valpromide (VPM).
• To investigate the scientific basis for the differing approved indications of these valproate derivatives.

Main Methods:

• Literature review of comparative studies focusing on VPA, DVP, and VPM.
• Analysis included efficacy, pharmacokinetic parameters, adverse effects, and cost data.
• Specifically examined studies comparing valproic acid (VA) with divalproex (DVP).

Main Results:

• No significant differences in efficacy for epilepsy or mood disorders were found in eight efficacy studies comparing VA and DVP.
• Ten studies reported inconsistent findings regarding gastrointestinal side effects between formulations.
• DVP demonstrated bioequivalence to VA but with a longer Tmax; VPM showed lower bioavailability (80%) and delayed Tmax.
• DVP and VPM incur higher costs compared to VA.

Conclusions:

• The current distinct indications for valproate derivatives (VPA, DVP, VPM) appear not to be scientifically justified.
• Interchangeability between VA and DVP in bipolar disorder treatment is plausible at equivalent dosages.
• Switching to VPM from VA may necessitate adjusted dosing schedules and a 20% dose reduction.